logo

Beigene (BGNE)



Trade BGNE now with
  Date
  Headline
6/15/2018 2:26:15 AM BeiGene Provides Development Update And Presents Clinical Data On Zanubrutinib
5/17/2018 7:07:25 AM BeiGene Begins Phase 3 Trial Of Pamiparib As Maintenance Therapy In Chinese Patients With Ovarian Cancer
4/16/2018 7:05:11 AM BeiGene Begins Phase 2 Trial Of Tislelizumab In Relapsed Or Refractory Mature T-and NK-Cell Lymphomas
4/10/2018 7:04:37 AM BeiGene Initiates Global Phase 2 Trial Of Anti-PD-1 Antibody Tislelizumab For HCC Or Liver Cancer
2/5/2018 6:17:16 PM BeiGene Reports Commercial Availability Of VIDAZA (Azacitidine For Injection) In China
1/31/2018 6:06:20 AM BeiGene Begins Global Phase 3 Trial Of Anti-PD-1 Antibody Tislelizumab For Esophageal Squamous Cell Carcinoma
1/17/2018 11:25:37 PM BeiGene Announces Pricing Of Follow-on Public Offering Of 7.43 Mln ADSs At $101/ADS
1/8/2018 6:06:32 AM BeiGene And Mirati Therapeutics Announce Exclusive License Agreement For Sitravatinib In The Asia Pacific Region
1/2/2018 6:01:57 AM BeiGene Initiates Global Phase 3 Trial Of Anti-PD-1 Antibody Tislelizumab In Patients With Hepatocellular Carcinoma
12/18/2017 6:02:34 AM BeiGene Initiates Pivotal Trial Of PARP Inhibitor Pamiparib In China In Patients With Ovarian Cancer
12/11/2017 10:09:23 AM BeiGene Presents Initial Phase 1b Data For Zanubrutinib (BGB-3111) Plus PD-1 Antibody Tislelizumab (BGB-A317)